MGX
Price
$1.73
Change
+$0.07 (+4.22%)
Updated
Jun 6 closing price
Capitalization
64.67M
67 days until earnings call
SABS
Price
$1.81
Change
-$0.02 (-1.09%)
Updated
Jun 6 closing price
Capitalization
16.82M
Interact to see
Advertisement

MGX vs SABS

Header iconMGX vs SABS Comparison
Open Charts MGX vs SABSBanner chart's image
Metagenomi
Price$1.73
Change+$0.07 (+4.22%)
Volume$502.12K
Capitalization64.67M
SAB Biotherapeutics
Price$1.81
Change-$0.02 (-1.09%)
Volume$2.41K
Capitalization16.82M
MGX vs SABS Comparison Chart
Loading...
MGX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
SABS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
MGX vs. SABS commentary
Jun 07, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is MGX is a StrongBuy and SABS is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Jun 07, 2025
Stock price -- (MGX: $1.73 vs. SABS: $1.81)
Brand notoriety: MGX and SABS are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: MGX: 150% vs. SABS: 5%
Market capitalization -- MGX: $64.67M vs. SABS: $16.82M
MGX [@Biotechnology] is valued at $64.67M. SABS’s [@Biotechnology] market capitalization is $16.82M. The market cap for tickers in the [@Biotechnology] industry ranges from $324.3B to $0. The average market capitalization across the [@Biotechnology] industry is $2.35B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

MGX’s FA Score shows that 1 FA rating(s) are green whileSABS’s FA Score has 0 green FA rating(s).

  • MGX’s FA Score: 1 green, 4 red.
  • SABS’s FA Score: 0 green, 5 red.
According to our system of comparison, both MGX and SABS are a bad buy in the long-term.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

MGX’s TA Score shows that 6 TA indicator(s) are bullish while SABS’s TA Score has 5 bullish TA indicator(s).

  • MGX’s TA Score: 6 bullish, 2 bearish.
  • SABS’s TA Score: 5 bullish, 4 bearish.
According to our system of comparison, MGX is a better buy in the short-term than SABS.

Price Growth

MGX (@Biotechnology) experienced а +1.76% price change this week, while SABS (@Biotechnology) price change was -6.22% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +9.04%. For the same industry, the average monthly price growth was +14.90%, and the average quarterly price growth was +1.90%.

Reported Earning Dates

MGX is expected to report earnings on Aug 13, 2025.

SABS is expected to report earnings on May 09, 2025.

Industries' Descriptions

@Biotechnology (+9.04% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
MGX($64.7M) has a higher market cap than SABS($16.8M). MGX (-52.078) and SABS (-52.296) have similar YTD gains . SABS has higher annual earnings (EBITDA): -40.29M vs. MGX (-65.06M). MGX has more cash in the bank: 275M vs. SABS (30.4M). SABS has less debt than MGX: SABS (4.52M) vs MGX (46.1M). MGX has higher revenues than SABS: MGX (55.1M) vs SABS (0).
MGXSABSMGX / SABS
Capitalization64.7M16.8M385%
EBITDA-65.06M-40.29M161%
Gain YTD-52.078-52.296100%
P/E RatioN/AN/A-
Revenue55.1M0-
Total Cash275M30.4M905%
Total Debt46.1M4.52M1,020%
TECHNICAL ANALYSIS
Technical Analysis
MGXSABS
RSI
ODDS (%)
N/A
Bearish Trend 1 day ago
86%
Stochastic
ODDS (%)
Bearish Trend 1 day ago
90%
Bullish Trend 1 day ago
74%
Momentum
ODDS (%)
Bullish Trend 1 day ago
68%
Bullish Trend 1 day ago
56%
MACD
ODDS (%)
Bullish Trend 1 day ago
78%
Bearish Trend 1 day ago
79%
TrendWeek
ODDS (%)
Bullish Trend 1 day ago
78%
Bearish Trend 1 day ago
83%
TrendMonth
ODDS (%)
Bullish Trend 1 day ago
84%
Bullish Trend 1 day ago
67%
Advances
ODDS (%)
Bullish Trend 5 days ago
78%
Bullish Trend 9 days ago
71%
Declines
ODDS (%)
Bearish Trend 3 days ago
90%
Bearish Trend 1 day ago
88%
BollingerBands
ODDS (%)
N/A
Bearish Trend 1 day ago
88%
Aroon
ODDS (%)
Bullish Trend 1 day ago
90%
Bullish Trend 1 day ago
70%
View a ticker or compare two or three
Interact to see
Advertisement
MGX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
SABS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
FCUPX19.200.14
+0.73%
NYLI PineStone U.S. Equity Class P
IBARX24.330.08
+0.33%
Macquarie Balanced Fund Class R6
HSMYX12.16N/A
N/A
Hartford Small Cap Value Y
HEQCX5.32N/A
N/A
Monteagle Opportunity Equity Instl
BTEKX75.46N/A
N/A
BlackRock Technology Opportunities K

MGX and

Correlation & Price change

A.I.dvisor indicates that over the last year, MGX has been loosely correlated with KOD. These tickers have moved in lockstep 42% of the time. This A.I.-generated data suggests there is some statistical probability that if MGX jumps, then KOD could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To MGX
1D Price
Change %
MGX100%
+4.22%
KOD - MGX
42%
Loosely correlated
+7.65%
VERV - MGX
38%
Loosely correlated
+8.12%
KYTX - MGX
35%
Loosely correlated
+15.31%
IMNM - MGX
35%
Loosely correlated
+0.11%
CVM - MGX
33%
Poorly correlated
+0.85%
More

SABS and

Correlation & Price change

A.I.dvisor indicates that over the last year, SABS has been loosely correlated with LPTX. These tickers have moved in lockstep 48% of the time. This A.I.-generated data suggests there is some statistical probability that if SABS jumps, then LPTX could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To SABS
1D Price
Change %
SABS100%
-1.36%
LPTX - SABS
48%
Loosely correlated
-0.56%
MGX - SABS
33%
Poorly correlated
+4.22%
HOOK - SABS
30%
Poorly correlated
+1.96%
SLS - SABS
29%
Poorly correlated
-1.23%
INKT - SABS
29%
Poorly correlated
-0.48%
More